Order Article Reprints

Gras Navarro A, Espedal H, Joseph JV, Trachsel-Moncho L, Bahador M, Tore Gjertsen B, Klæboe Kristoffersen E, Simonsen A, Miletic H, Øyvind Enger P, et al. Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival. Cancers. 2019; 11(7):996. https://doi.org/10.3390/cancers11070996

Gras Navarro, Andrea, Heidi Espedal, Justin Vareecal Joseph, Laura Trachsel-Moncho, Marzieh Bahador, Bjørn Tore Gjertsen, Einar Klæboe Kristoffersen, Anne Simonsen, Hrvoje Miletic, Per Øyvind Enger, and et al. 2019. "Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival" Cancers 11, no. 7: 996. https://doi.org/10.3390/cancers11070996

Gras Navarro, A., Espedal, H., Joseph, J. V., Trachsel-Moncho, L., Bahador, M., Tore Gjertsen, B., Klæboe Kristoffersen, E., Simonsen, A., Miletic, H., Øyvind Enger, P., Rahman, M. A., & Chekenya, M. (2019). Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival. Cancers, 11(7), 996. https://doi.org/10.3390/cancers11070996